ctDNA in Pancreatic and Colorectal Cancer

The present role of minimal residual disease in solid tumor cancers, and current evaluations further exploring its potential in pancreatic and colorectal cancer.

An overview of the ctDNA testing platforms and the potential clinical applications of ctDNA testing across the colorectal cancer disease continuum.

The potential clinical applications of ctDNA analyses in pancreatic cancer.

How ctDNA testing can be used in the preoperative and postoperative settings to help oncologists make informed treatment decisions.

Dr Gregory P. Botta reacts to results of a study that recently explored the association of tumor-informed and personalized ctDNA with patient survival outcomes in pancreatic cancer, as presented at ASCO GI 2022.

Key takeaways of a recent article highlighting the use of ctDNA analyses for the assessment of recurrence risk, benefit of adjuvant therapy, and early relapse detection after treatment in colorectal cancer patients.

Current trials investigating the potential of ctDNA analyses in pancreatic cancer.

Implications of the GALAXY study in CIRCULATE-Japan, in terms of utilizing ctDNA to guide decisions for adjuvant chemotherapy in colorectal cancer.

What to know about the design and results of the CIRCULATE-Japan study in colorectal cancer, in terms of using ctDNA analyses to help inform treatment decisions in the postoperative setting.

An overview of the design of the CIRCULATE-US study, set to further explore the potential of ctDNA testing in colorectal cancer.

Gregory P. Botta, MD, PhD, highlights key trials of interest exploring ctDNA analyses to better inform treatment decisions for patients with rectal cancers.

Abstracts presented during ASCO GI 2022 and other initiatives in clinical trials, assessing treatment strategies for patients with colorectal cancer based on ctDNA negativity or positivity.

Advice to GI oncologists in the community on using ctDNA testing to detect minimal residual disease and inform treatment decisions in colorectal cancer.